KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC

BACKGROUND: Programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1) inhibitors represent novel therapeutic options for advanced non-small cell lung cancer (NSCLC). However, approximately 50% of patients do not benefit from therapy and experience rapid disease progression. PD-L1 expression is the only...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Ther Adv Med Oncol
Hoofdauteurs: Cinausero, Marika, Laprovitera, Noemi, De Maglio, Giovanna, Gerratana, Lorenzo, Riefolo, Mattia, Macerelli, Marianna, Fiorentino, Michelangelo, Porcellini, Elisa, Buoro, Vanessa, Gelsomino, Francesco, Squadrilli, Anna, Fasola, Gianpiero, Negrini, Massimo, Tiseo, Marcello, Ferracin, Manuela, Ardizzoni, Andrea
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: SAGE Publications 2019
Onderwerpen:
Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6859675/
https://ncbi.nlm.nih.gov/pubmed/31798692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919885540
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items